Professional Medical Expertise Company (TADAWUL:9574)

TADAWUL:9574 Cash Flow Statement

Financials in millions SAR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	27.65	24.84	19.02	20.62	9.3
Depreciation & Amortization	6.63	5.45	3.07	2.37	1.92
Loss (Gain) From Sale of Assets	-1.44	-1.09	-0	0.06	0.42
Provision & Write-off of Bad Debts	3.8	2.79	2.39	0.44	0.5
Other Operating Activities	12.79	7.99	6.23	4.2	1.79
Change in Accounts Receivable	-6.51	-37.55	-14.57	-33.12	7.81
Change in Inventory	-32.3	-40.43	-25.19	-13.39	-10.44
Change in Accounts Payable	-7.6	47.69	6.95	28.71	-3.77
Change in Other Net Operating Assets	-4.91	-3.82	-1.82	11.14	4.47
Operating Cash Flow	-1.88	5.88	-3.92	21.03	11.99
Operating Cash Flow Growth	-	-	-	75.31%	-
Capital Expenditures	-6.58	-8.98	-6.51	-3.34	-2.06
Sale of Property, Plant & Equipment	3.47	2.18	0.12	-	-
Cash Acquisitions	-	-	-	-	-0.23
Investing Cash Flow	-3.11	-6.8	-6.39	-3.34	-2.29
Short-Term Debt Issued	31.12	4.66	18.79	0.63	10.66
Total Debt Issued	31.12	4.66	18.79	0.63	10.66
Long-Term Debt Repaid	-1.85	-1.94	-0.63	-0.47	-0.28
Net Debt Issued (Repaid)	29.27	2.72	18.16	0.16	10.38
Issuance of Common Stock	-	-	-	-	0.03
Common Dividends Paid	-9.98	-	-16	-2.9	-17.1
Other Financing Activities	-10.37	-6.16	-4.33	-2.52	-1.28
Financing Cash Flow	8.93	-3.44	-2.17	-5.26	-7.98
Miscellaneous Cash Flow Adjustments	-	-	-	-	0.07
Net Cash Flow	3.94	-4.36	-12.49	12.43	1.79
Free Cash Flow	-8.46	-3.1	-10.43	17.69	9.93
Free Cash Flow Growth	-	-	-	78.03%	-
Free Cash Flow Margin	-2.70%	-1.24%	-5.93%	13.48%	13.35%
Free Cash Flow Per Share	-2.42	-0.89	-4.67	22.93	-
Cash Interest Paid	10.37	6.16	4.33	2.52	1.28
Levered Free Cash Flow	-29.59	-17.53	-48.33	9.68	-
Unlevered Free Cash Flow	-22.83	-13.38	-48.33	9.68	-
Change in Working Capital	-51.32	-34.11	-34.63	-6.66	-1.93

Updated Sep 8, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.